OBJECTIVES: The objective of this study is to assess the characteristics of relapsing remitting multiple sclerosis (RRMS) patients taking disease modifying therapies (DMTs) in the US.  METHODS: A large US administrative retrospective claims database was used to identify patients diagnosed with RRMS and were prescribed DMTs between January 2010 to December 2012 were included in the study. All patients were ≤ 17 years of age and continuously enrolled in the same health plan for a year. Descriptive statistics and chi-square tests were performed on the data. RESULTS: There were a total of 359 patients that met the study inclusion criteria. The mean age of the patients was 14.19 ± 2.29 years, 61.6% of the patients were females, and majority of the patients were between 12 and 17 years of age (85.5%). Thirty three percent of the patients were from East, 20.1% were from Midwest, 36.2% from South and 10.6% is from West region. 59.6% of the patients were on a group coverage plan and 49.3% of the patients were on a DMT prescription that is under their health plan formulary. Majority of the patients (95%) were prescribed 30 days’ supply of DMTs, 1.7% were on 60 days’ supply and 3.3% were on 90 days’ supply of DMTs. More than half of the patients (53.8%) were diagnosed with mental health problems in addition to their RRMS as a primary diagnosis. On average, patients were continuously enrolled for 5.10 ± 1.74 years and submitting around 466 claims during this period.  CONCLUSIONS: The majority of the pediatric patients were teenagers and females. One third of the patients was from south and received on average a 30 days’ supply of DMT.